Tag: investing

All investing related articles are found here. Educative, informative and written clearly.

  • O2Micro International Limited – Penny Stock To Buy

    O2Micro International Limited – Penny Stock To Buy

    O2Micro International Limited - Penny Stock To BuyO2Micro International Limited increased the Q4 2019 revenue forecast to be at a $17 million range.
    This stock is a good short-term opportunity

    By Guy Avtalyon

    O2Micro International Limited is a penny stock and recently the company announced great revenue for the third quarter. The revenue was up by about 12%. Moreover, several days ago the company raised revenue forecast for Q4. And investors noticed it. Yes, the price of shares dropped on Friday, December 6 for 1.36% and the current price is at a bit more than $1.73. 

     

    But what makes us think it is a good stock to be watched in December?

    According to Reuters, O2Micro International Limited develops, produces and sells components for power management. They are supplying producers of computers, the communication industry, automotive. O2Micro International Limited produces integrated circuits for LCDs and for LED, desktop and notebook monitors, digital cameras, electric bikes, LEVs (low emission vehicles) apps, smartphones, GPS, etc.

    O2Micro International Limited financial highlights for the third quarter 

    O2Micro International Limited reported Q3 revenue of $16.0 million. It was up 12.3% but lower 4.7% from the same quarter last year. The gross margin in the last reported quarter was 51.4%. It is higher from 50.1% in the second quarter and by 50.5% higher than in the third quarter of last year. The company kept the gross margin in the targeted range. 

    O2Micro International Limited reported that over the third quarter it recorded total GAAP operating expenses of $9.4 million. For the second quarter, it was $9.7 million. In its Q3 report, we could see the GAAP loss of $200,000, while in the Q2 it was $2.8 million.

    GAAP net loss per fully diluted ADS was $0.01 in Q3 this year, in Q2 it was $0.11 and for the third quarter last year, it was $0.13.

    The future of OIIM stock price

    In our opinion, O2Micro International Limited stock isn’t a good long-term investment. It is still a high-risk long-term investment. But if you prefer short-term investing, not longer than 3 months, this could be a good choice. Traders Paradise sees this stock at the lowest price at $1.90 in the next 14 days. But be prepared for several jumps and falls during that time. Our data shows that this stock was in the uptrend in the past 12 months and this will continue over the next 3 months since the stock is in rising tendency. 

    Actually, the stock is in the middle of a strong and wide uptrend. In the short term, it isn’t bad since it could rise around 29% in the next 3 months and hit the price between $1.90 and $2.40 at the end of that period.

    Bottom line

    On December, 2 O2Micro International Limited (NASDAQ: OIIM) increased the Q4 2019 revenue forecast to be in the mid to high $17 million range. That is for one million more than the company reported in its Q3. 

    Does it mean that the management has some trump card to show in the coming months? We believe the answer is yes. 

    Don’t miss this: Investing In Penny Stocks Can Be A Highly Profitable Strategy

    There is a buy signal coming from the relation between short and long moving average. If the stock price breaks down somewhere between $1.70 and $1.50, which are the support levels, the sell signal will be issued. Well, some negative signal is already issued. On December, 4 a sales signal came from a pivot top point. That means further falls until a new bottom pivot has been found. Traders should know that the volume of this stock fell by 4 590 with the dropping stock price. Technically speaking, it is good. But the risk may come from the low liquidity.

    The stock has several short-term signals and a good trend. That’s why we think that there is a buying opportunity for the short-term.

     

  • Vanguard Health Care Index Fund ETF Shares (VHT)

    Vanguard Health Care Index Fund ETF Shares (VHT)

    Vanguard Health Care Index Fund ETF
    Healthcare ETF is good for investors with less risk tolerance
    Vanguard Health Care Index Fund ETF is one of the largest in the stock market

    Vanguard Health Care Index Fund ETF is focused on stocks in the U.S. health care sector. It is managed by Vanguard and is covering health care stocks in the U.S. stock market. It is a big fund that holds shares of 388 companies. The Fund owns shares of Pfizer Inc, Merck & Co, AbbVie Inc., Johnson & Johnson, UnitedHealth Group Inc., and Abbott Labs. Its 10 top holdings account for almost 45% of the portfolio. But the fund has an extremely good diversified portfolio. It has holdings in pharmaceuticals, biotechnology, health care equipment, health care, supplies, facilities, services, technology, distributors, and life sciences tools and services.

    Healthcare stocks are hot

    Everyone needs health care and everywhere. But the main source comes from boomers. We have nothing against them, but the truth is that as people are aging, they need more health care. Correlated with this is the increased demand for medical products. But this isn’t the whole truth. 

    Also, there is great progress in new technologies that are likely to create great growth for companies in this industry. 

    For example, pharmaceuticals. You can see drugmakers that are developing new procedures, new methods, and drugs. Today we have personalized therapy, based on personal genetic data for each patient individually. This is especially important for cancer treatment, for example.

    Today, biotechs and pharmaceutical companies are practicing gene editing as the treatment for rare genetic diseases.

    The healthcare field is huge and connected. For instance, for early diagnosis of cancer, the liquid biopsy is very popular today and accurate. But someone had to develop it. The same is with AIs and robotics, medical device companies are developing new types of high-tech equipment. So many companies are involved to improve healthcare services. Look at the telehealth, it is adopted broadly. We have robots as surgeons. Monitoring patients with chronic diseases out of hospitals is easier than ever.  

    These products are not aimed at older populations only. Also, we have great progress in aesthetics, skincare, body care, hygiene, etc. 

    Can you see now why healthcare is a hot zone of interest for investors?

    Vanguard Health Care Index Fund ETF Shares 

    Vanguard discovered the ETFs. 

    It tracks the performance of the MSCI U.S. Investable Market Index (IMI)/Health Care 25/50.  

    This ETF has delivered an average annual return of 9.47% since it started in 2004. It has generated average annual returns of 9.78% over the last three years and 9.2% over the last five years.

    The Fund’s dividend yield is of 2,1%, the expense ratio 0.10% which is one of the lowest among ETFs.

    Vanguard Health Care Index Fund ETF

    Vanguard Health Care gives wide exposure. VHT stock is cheap to hold. Its liquidity is strong. The problem is the same as with other Vanguard funds. It is restricted transparency since the holdings are published monthly with 2 weeks delay.

    Still, for the long- term investors a reduction of transparency shouldn’t so much important. VHT fell by -0.13% on Thursday, December 5, but rose for 0,69% on Friday, December 6. The current price is $187.93, $1.29 more than the previous one. Daily fluctuation of stock was 0.79%, a day high was $188.50, a day low was $187.02.

    During the last 2 weeks, the stock price was shifting up and down but still, the 2-weeks gain was 2.78%.
    Since the volume has increased by 47 673 shares on falling prices, you should take this as an early sign of increasing risk in the next several days. Anyway, the price is dropping so it is time to buy it.

    According to analysts, the stock is in the upper line of a rising trend in the short term. This can be a very good selling chance for the short-term traders because the move towards the lower band of the trend can be expected.
    If the price breaks up the top trend line at $188.45 it is expected to increase by 11.09% in the next 3 months with a price between $195 and $210 at the end of this period.

    Bottom line

    Investing in a healthcare ETF decreases the risks for investors thanks to a diversified portfolio across various stocks.
    Moreover, ETFs can modify their holdings when it is necessary. Also, healthcare ETFs can resist during economic downturns because we will all need medical care no matter if it a crisis or not. But keep in mind, ETFs can drop during the crisis or recession too. They are not immune. But as the lesson from 2008, when some ETFs dropped by two-digit percentages, they had been rising again and did it fast.
    For trading stocks use our FREE Trading Exit Strategy, to calculate and optimize the numberless exit strategies, an app that you have for the first time in history.

    Featured image credit: *Total Shape*

  • Revance Therapeutics – A Wrinkle-Causing Year

    Revance Therapeutics – A Wrinkle-Causing Year

    Revance Therapeutics - A Wrinkle-Causing YearThe company is a biotech pioneer establishing a new category of long-lasting neuromodulators.
    The Revance Therapeutics stock can be a good addition to the investment portfolio 

    by Guy Avtalyon

    Wednesday was a rough day for shares of Revance Therapeutics (NASDAQ: RVNC). Investors were surprised by lowered the biotech stock for 16.4%  on Wednesday and traded at $16.61.

    Only a few days ago, or the day before, the shares had been rising. But the company submitted an application to the FDA for DAXI in November. On Monday, shares rose over $20 per share until the end of Tuesday’s session. On Wednesday it was announced $17 per share. 

     

    What happened with DAXI?

    For a long time, DAXI is a neurotoxin, but better than Botox, a global favorite. Revance Therapeutics has proof that it works better. Botox sales have risen to $2.7 billion per year and the producer AbbVie has a lot of reasons to be satisfied. 

    But let’s go back to Revance

    FDA’s evaluation of DAXI could take months and we still don’t know if and when it will start. Revance Therapeutics’ partner Mylan announced the possibility to fund late-stage development of DAXI until April 30, 2020. What if FDA doesn’t start its review until then? You see, despite a published good result of DAXI and great expectations for selling it, one paper can disappoint investors. Yes, it is an important paper and a lot of things depend on it. For example, the future of Revance Therapeutics and its partnership with Mylan.

    If Mylan supports DAXI and gives Revance a two-digit percentage on sales, it could deliver a great return. 

    On an investment of $10.000 in less than 2 months, you may have a nice return of $1.047 if you set your stop-loss at 19,25% level from the current price and take-profit at 40,25% level. But once again check yourself.

    Revance Therapeutics had the problematic announcement 

    Revance Therapeutics, Inc. is a biotech company. It develops next-generation neurotoxins for treating aesthetic and therapeutic conditions. On December 4, it announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price of $17.00 per share. 

    Revance has allowed the underwriters a 30-day option to buy up to 975.000 additional shares. The gross incomes from the offering are expected to be approximately $110.5 million. The offering is supposed to close about December 6, 2019. Revance Therapeutics plans to use this net profit of common stock to proceed to fund the commercialization of DAXI. The additional income will spend mostly on research and development.

    Revance Therapeutics

    Revance is fusing new science with the entrepreneurial vision of Silicon Valley. It is a modern biotech company with an innovative approach to aesthetic and therapeutic treatments.

    The company stated on its website:
    “Our lead investigational product, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.”

    It has been completed a Phase 3 program for DAXI in grimace lines. It showed fantastic efficiency and duration, and the company is seeking FDA approval.
    The company is focused on developing products and treatments in dermatology and aesthetics. Its products are RT001, botulinum toxin type A (BoNT-A) for cosmetic and dermatologic treatments. The previous name of the company was Essentia Biosystems, Inc. Under the name Revance Therapeutics, Inc. it is founded in 2002 with headquarters in Mountain View, California.

    As Traders Paradise can conclude the stock price of Revance Therapeutics can easily hit at least $18 in the next 10 days.

    At the moment of writing this article, it is December 05, Thursday, the current price of RVNC stock is $16.840 which is a bit more than yesterday. This stock had a declining tendency for the past 12 months. Biotech stocks are really tricky. But Traders Paradise thinks the stock price could rise significantly in the next 2 months. Over the one year, the price could be almost doubled. Hence, this is a strong BUY stock.

  • Biotech Stocks Are A Good Investment

    Biotech Stocks Are A Good Investment

    Biotech Stocks Are A Good Investment
    The biotech companies have strong earnings growth
    The Nasdaq Biotech Index (NBI) has slightly outpaced the S&P 500 over the past 12 months.

    Biotech stocks are the most impressive, exciting and, at the same time, one of the trickiest assets of the stock market. Biotech firms use technological methods based on science to produce products. The majority of biotech companies are focused on clinical research and the development of new medicines. 

    But the whole industry has a lot of different purposes, the drugs are just a part of that. You can find biotech stocks on genetic experimentation, food modifications, health care, almost everywhere. One thing is common for every single producer: they have to go through a harsh, expensive and intensive experimental process before getting approval for the market.

    The biotech companies have strong earnings growth 

     Discovering the best biotech firms to invest in can be difficult. Laboratory ideas don’t always come to success and frequently biotech stocks are subject to strict regulations and rules.

    What you have to keep in mind is earnings growth. Biotech stocks are giving exactly that. If you are looking for great rewards, the biotech stocks are for you. One thing is important to be noticed here: these stocks carry a big risk too.

    Biotech stocks have great potential

    Well, there is an explanation of why that is. Every company needs time to develop its business, operations, presence in the market. Biotech companies frequently depend on the success of several trials of their products. During that phase, its stock isn’t expensive. Contrary, it can be very cheap. When the company gets approval for a drug or some positive news about testing comes, the stock price can skyrocket. Refusals or bans, though, can cause a disaster. So, for normal investors, it can be difficult to gauge how the testing of some drugs or anything from the field of the biotech industry will end. Well, here is one suggestion. Stay tuned on what the analysts who are well informed in the biotech industry are saying. If you see a stock that is frequently surrounded by bulls, it is a sign that something worth is nearby. 

    Recognize your biotech stock better than anyone

    We will show one example of how to do so.

    Axsome Therapeutics is developing new drugs for the treatment of CNS disorders. Yes, it is clinical-testing stage and biotech stocks can be uncertain for investors. But this stock is remarkably fit for any investor with an aggressive approach to investment.

    AXSM stock has increased over 1.200% in this year. The investors are excited about the upcoming clinical study results. Axsome Therapeutics is in a late-stage study for its AXS-05. It is innovative and important in treating a depressive disorder, so-called MDD. The company is expecting results from another study, a drug for treating treatment-resistant depression, by the end of the first quarter in 2020. Also, the company expects positive results from a study of AXS-05 for Alzheimer’s disease in the first six months of 2020. And stock market analysts are predicting a huge revenue for the company and the shareholders. So, the hint that some biotech stock is a good investment is coming from the news.

    How to pick the best biotech stocks

    Over the past year, the Nasdaq Biotech Index (NBI) has kept up with the market.
    This year has been a hard ride for everyone. But the biotech sector, with its large firms, is definitely catching its pace. The index is rising. We were witnesses of interesting mergers during the past several years that starting to be profitable. Some new technologies are starting to gain excellent results which boosts hope for many patients. The cost of their tests is enormous, it is around $2 billion approximately. Also, it takes almost 10 years until some drug gets permission for distribution and human usage.
    It sounds like a lot of responsibility. Moreover, producers need to form a strong base for future growth.

    If you are focused on biotech stocks you should find biotech companies that are driving cutting-edge therapies. The brands that are well-positioned provide big premiums.

    Traders-Paradise recently wrote about one of them, but stay tuned, there will be more.

  • Axsome Therapeutics (AXSM) Is A Good Investment

    Axsome Therapeutics (AXSM) Is A Good Investment

    Axsome Therapeutics (AXSM) Is A Good InvestmentAxsome Therapeutics gained 1.70% in the last trading day ( Friday, Nov 29), increasing from $38.71 to $ 39.37. Will the company be able to continue growing?

    By Guy Avtalyon

    Axsome Therapeutics is developing innovative therapies for the treatment of CNS disorders. Yes, clinical-stage biotech stocks can be a risky suggestion for investors. Well, at the same time this stock is extremely suitable for any dynamic investors. If you prefer an aggressive approach to your investment this stock deserves your attention.

    Axsome Therapeutics (AXSM) has jumped over 1.200% in this year. The investors are awaiting the biotech’s upcoming clinical study results excited. Well, the company is in a late-stage study for its AXS-05. It is innovative and important in treating a depressive disorder, so-called MDD to the end of the year. The company is awaiting results from another study, a drug for treating treatment-resistant depression and it will be published to the end of the first quarter in 2020. Also, Axsome Therapeutics expects to present excellent results from a study of AXS-05 for Alzheimer’s disease in the first six months of 2020. 

    To the end of this year, the company is expected to present the results from a late-stage study of AXS-07 in treating migraine and of AXS-12 in treating narcolepsy. Analysts estimate AXS-05 could obtain annual sales of more than $1 billion when approved. 

    The main problem is that Axsome Therapeutics’ results could be failed like it is with so many drugs.
    But if they get a good result this stock will be high rocketed. 

    The current price is $39.37 (Nov 29). This small-cap stock in the S&P 500 had the greatest total return over the past 12 months. It is 959.6%

     

    Why invest in Axsome Therapeutics

    Axsome Therapeutics, Inc can be a profitable investment option for investors wanting good returns. Axsome Therapeutics, Inc quote is $39.370 on December 2. This stock can provide more than 300% of revenue after 5 years since it is expected the price to rise to $160 in the next year.

    Axsome Therapeutics has a median target of $46.50, where a high estimate of $53.00 and a low estimate of $25.00. The median estimate represents a +18.11% jump from the current price. The investment analysts’ suggestion is to buy this stock. 

    Axsome Therapeutics ABOUT

    The company’s market cap is $1.36B. Axsome Therapeutics reported Q3 2019 financial results on Nov 7, 2019.

    Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops innovative treatments for CNS disorders, especially for those with limited treatment possibilities. Axsome’s center CNS product portfolio covers four clinical-stage products, AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is in a phase 3 test in treatment-resistant depression, the same as MDD, and a Phase 2/3 trial in difficulties connected with Alzheimer’s disease. AXS-05 is also being developed for smoking end therapy. AXS-07 is in two Phase 3 trials for the treatment of migraine. AXS-12 is in a Phase 2 trial in narcolepsy.

    AXS-05, AXS-07, AXS-09, and AXS-12 are drug products not approved by the FDA. For more specific information, you have to visit the company’s website. The Company may occasionally disseminate material, nonpublic information on the company website.

    Is AXSM a good investment?

    This company’s liquidity data is interesting: its Quick Ratio is 1.41 and its Current Ratio is 1.41. This shows a good ratio between its short-term liquid assets and its short-term liabilities. So we can easily conclude it is a less risky investment. This stock’s RSI score is at 50.78, which means that the stock is not oversold or overbought.
    The important clinical wins could place this company on the route to produce greater gains. Hence, we think it is a good investment.

     

  • Walmart Eagerly Awaits Black Friday and Cyber Monday

    Walmart Eagerly Awaits Black Friday and Cyber Monday

    Walmart Expects Black Friday and Cyber Monday To Come
    Walmart is one of the biggest companies in the world and capable to resist the competition.
    The stock price dropped but it easily can go up very soon

    Walmart (NYSE:WMT) is transforming and this retailer is ready for Black Friday and Cyber Monday. Everything is in place, so shopping can start. These two holidays are a great test for Christmas. After Black Friday and Cyber Monday, the possibility for Walmart’s stock price to rise is real and even before Christmas. The current price is $118.92 and it dropped by 0.37% from the previous price. But the price rose after hours to &118.95.

    Walmart Expects Black Friday and Cyber Monday To Come

    What makes us think shopping will increase?

    First of all, the unemployment rate is lower than in the last 50 years, job growth is stable, salaries are rising. The St. Louis Fed published that the personal savings rate is at 8.3% which is the highest level since 2012. So, Americans will spend their money on holidays, there is no doubt. 

    The holidays are great for retailers and Walmart plays a big role since it has been transforming and has been aggressively investing in online. Three years ago Walmart bought Jet.com, a US online retailer and took a large stake in the JD.com, online retailer in China.

    Walmart grew its annual profit forecast because quarterly earnings beat estimates. Its shares have risen 26% and trade at 24 times earnings. 

    Well, when it comes to food, Walmart is ready. The grocery is very important for the company’s online business. Walmart customers can purchase groceries online, with unlimited delivery for $98 a year or $12.95 a month.
    E-commerce is a field where  Walmart can get this holiday season since online shopping is supposed to grow by 14% to 18% gaining $149 billion.

    But Walmart has already made profits. Walmart reported third-quarter e-commerce sales rose 41%, driven by growth in online grocery shopping. But Thanksgiving falls on Nov. 28 and the holiday shopping season is shorter by six days. This gives the company less opportunity for sales. 

     

    As always there is Amazon, Walmart’s rival. To beat the competition, Amazon announced some beneficial for its Prime members. Not for all, but still the grocery delivery will be free of charge.
    Management at Walmart announced the lower prices from electronics to playthings. Walmart, also, has shown that it can balance the other features of its businesses despite the Trade war.

    Walmart started offering holiday sales almost a week before Halloween this year. Well, the company called it Early Drop Deals, not Black Friday sales. The company opened its doors for the customers and made their Black Friday purchasing available earlier. Making this, the company actually spread Black Friday’s shopping over more days. 

     

    Walmart stock price and its future

    Walmart’s stock price dropped by 0.37% on  Monday, November 25. Now it has 3 days of dropping in a row. This could be an early signal the risk will be raised somewhat for the next few days and the stock price may slightly drop further. 

    Walmart is currently in the lower frame of a small and weak rising trend in the short term. This is usually a signal for a good buying opportunity. This short-term trend shows the stock is likely to rise by around 5% in the next 3 months and stay between $124 and $128.

    But Walmart stock is a good long-term investment since, as Traders Paradise can see, this stock is going to be profitable over a long period offering the revenue of almost 65%. Speaking about 5-years investment, for example, if you invest $1.000 right now your investment may grow to $1.600 at the end of that period. 

     

    Company’s ABOUT

    Walmart is one of the most profitable retailers in history. It is one of the most successful and well-known companies in the world.
    The company was founded in 1962 by Sam Walton, in Rogers, Arkansas with one store. To the end of 1968, the Walmart chain was expanded outside Arkansas and later opened the stores in every US state. In 1995, Walmart opened its first stores in Canada.
    From 1990, Walmart is the largest retailer in the U.S. and began to expand abroad, opening a store in Mexico and opened stores in the U.K., Germany, China.
    By 1999, Walmart wasn’t only the biggest private employer in the U.S. but in the whole world. Today it is the 29th company in the world, as Amazon, Alphabet, Microsoft or Apple with a host of Chinese companies, have passed Walmart by.
    By the second decade of this century, the chain had increased to over 11,000 stores in 28 countries.

     

  • The Kraft Heinz Company Is Bottoming

    The Kraft Heinz Company Is Bottoming

    The Kraft Heinz Company Is Bottoming
    The packaged-food giant reached rock bottom and positive signs are unfortunately weak. They are not enough to warrant a buy right now.

    The Kraft Heinz Company (NASDAQ: KHC) reported third-quarter 2019 financial results on October 31. The company reported lower net sales and higher input costs. So, the third quarter performances for this company were a lot below their potential but still, the company showed growth in comparison to the first six months this year.

    Kraft Heinz CEO Miguel Patricio said: “We are making good progress in identifying and addressing the root causes of past performance, as well as setting our strategic direction. Although there is still much work ahead, we’re encouraged by our improving performance, and are even more confident in our ability to turn around the Company and set a path of long term growth and profitability.”

    The Kraft Heinz Company results

    Net sales were $6.1 billion, and it was 4.8% below than it was in the same period last year.
    Net income increased to $899 million and diluted EPS increased to $0.74. Adjusted EBITDA declined 7.8% to $1.5 billion. The drop was caused by the drop in the United States and Canada, but there are higher overall corporate expenses also.
    The Board of Directors of the Kraft Heinz Company announced a quarterly dividend of $0.40 per share of common stock. It will be payable on December 13, 2019.
    The KHC stock was traded at $30.54 on Friday, November 22, which is an increase of 0.99%.

    The Kraft Heinz Company Is Bottoming

    Should you buy the Kraft Heinz Company stock?

    The analysts offering 12-month price predictions for Kraft Heinz Co have a median target of $32.00. Their high valuation is at $38.00 and a low at $23.00. The median shows a 4.78% rise from the current price.

    The recommendation is to hold stock in Kraft Heinz Co. 

    But the other group of analysts is pretty much sure that the Kraft Heinz stock couldn’t have good returns. That’s the reason why they claim that this stock is a bad and high-risk long-term investment. Today’s quote (Nov 25) for Kraft Heinz is $30.53 which is lower than on Friday. 

     

    Traders-Paradise opinion

    Having the current price of KHC stock in our mind and with the knowledge that the stock price had a downtrend for the past 1 year, we in Traders-Paradise are not sure is this stock is good as a long-term investment. We are close to thinking that this stock could easily drop significantly in the future hitting a decline of over 100% and to end up worthless. So, we suggest staying away from this stock if you are seeking a new addition to your investment portfolio. This is important especially if you are a new player on the market and don’t have enough experience. 

    This stock is trading in bear markets, which is harder for new traders.

    But if your plan is to buy and hold Kraft Heinz stock for a short time, for example, the next 10 days or two weeks, it can be a good choice. As we can see, the stock price could hit around $35 in the next several days.

     

    Bottom line

    The price line shows the possibility of zigzag running to the end of this year. After the end of this year, we are afraid that this stock will gain further declines.

    Our opinion comes from the suspicion that the company is not able to answer the challenges of predicting consumer demands. In its latest report, we couldn’t find that the company is ready to offer new products or to react to rivals’ improvements.
    The Kraft Heinz Company survives 150 years of challenging and produced some of the products well-known over the world. Yes, it is one of the largest global food companies, but the new era is already here and the company has to catch the moment.
    The point is that General Mills or Nestle are better choices in our opinion.
    We can recognize some possible upward movements, but they are weak and don’t provide enough reasons to buy this stock now.

     

  • The Top Winners And Top Losers In The Market

    The Top Winners And Top Losers In The Market

    The Top Winners And Top Losers In The Market
    Good and bad news may have a great influence on the stock price
    These two stocks show both sides, winning and losing on the market

    Top winners and top losers last week in the stock market is easy to find but what lies behind sometimes looks like a tricky part.
    For example, EyeGate Pharmaceuticals, Inc. (EYEG) is one of the winners last week. But what did make it become a winner? 

    The news about the high quality of its ocular bandage gel eye drops is able to provoke investors’ sentiment and confidence in the company. What did that news show us? The company is investing in research and development and improve its products. 

    And shares rose by more than 90%.

    The news that the company’s innovative eye-drop bandage worked better than the usual kinds of care. Its bandage contact lens, for the patients in need of corneal wound repair, is better than the others. EyeGate intends to submit a new application to the Food and Drug Administration in the first half of 2020.
    EyeGate CEO Stephen From said: “If approved, it will be the first product indicated to repair corneal defects, as well as the first prescription hyaluronic acid eye drops in the U.S.,” stated in a release. The company is expecting additional data this week. 

    And what happened? 

    The stock price jumped on good news.EyeGate shares rose on data for eye treatment data.

    The Top Winners And Top Losers In The Market

    Top winners and top losers last week are always the subject of investors’ attention. Yes, the stock price may jump on bad news too as well to drop on a good. Traders-Paradise wrote about it already.

     

    Let’s go a bit deeper in top losers. One of them is Pure Storage, Inc. (PSTG).

    Pure Storage (PSTG) stock dropped Friday after the company reported Q3 results on Thursday. The results missed Wall Street estimates. Pure Storage is a provider of data system technology. On Thursday last week, they reported an adjusted profit of 13 cents/share but Wall Street expected a profit of 9 cents. That was good but revenue of $428.4 million missed the estimation of $440 million. The company’s revenue was $11.4 million below estimation.

    The stock price dropped despite the fact that the company’s revenue grew 15% in comparison to the same period last year. The problem arose due to the fact that it was the slowest growth over 4 years.

    Pure Storage stock dropped 15.1%, closing at $16.86 on Friday.

    Top gainers often continue to rise and reach new highs with strong fundamentals. When a stock continues reaching new highs it’s essential to pay attention since there might be a retracement.

    Bottom line

    What Traders-Paradise thinks about those two stocks, the top winners and top losers?

    News reports about EYEG stock have been trending positive lately. That may easily cause optimism among investors and hence, the good news is likely to affect the stock price rising in the near future. So, this stock has a BUY signal. 

    EyeGate Pharmaceuticals, Inc stock is a good long-term investment. If you are seeking stocks with stable returns, this one can be a beneficial investment choice. EyeGate Pharmaceuticals, Inc was traded at $7.090 last Friday. We are expecting a further increase in the next years. This stock may reach $14 in the next 4 years. If you invest $1.000 today you may have $2.000 at the end of that period since the revenue is expected to be about 100%.
    This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 26.89 million shares bought and sold for approximately $453.37 million.

    On the other hand, Pure Storage, Inc stock can be a bad long-term investment and high-risk investment option.
    Pure Storage, Inc was traded at $16.860 on Friday last week. It dropped from $19.85 and that marked a fall of 3 days in a row. Volume has grown in the last day by 21.42 million shares but on dropping prices. The Traders-Paradise opinion is the stock will continue to fall in the days ahead and your investment may be decreased in the future. 

     

  • Levi Strauss On The Market Again

    Levi Strauss On The Market Again

    Levi Strauss On The Market Again
    Levi Strauss & Co. trades on the NYSE under the ticker symbol LEVI.
    This famous brand promises to be a good investment

    By Guy Avtalyon

    Levi Strauss is riding again.
    We are sure you have several of Levi’s products. When say Levi’s you mean eternity. Levi’s jeans is always IN. This denim cloth producer went public in March this year. The jeans on the trading floor. Sounds good even if it didn’t change the dress-code there. Actually, that decision was the second appearance of Levi’s on the stock market. 

    Firstly, the company was listed in the 1970s. But 15 years later, the company was taken private. Descendants of Strauss, well-known the Haas family bought it out. In March this year, that decision was changed and Levi’s is listed again on the NYSE under the ticker symbol LEVI. Levi’s started trading publicly for the second time in its 165-year history.

    At that time, the shares were priced at $17 and grew 32% in the first trading day. On the closing bell, the price was $22.41 and the valuation was over $8.5 billion.

    The LEVI price history

    The LEVI price history isn’t long but we can see that it had a few good trading weeks after went public. The price dropped in August and was traded at about $16. In October, the price increased to almost $20 but dropped again at $17 and stabilized in that area.

     

    On November 21 the LEVY was traded at $16.57 which was an increase of 0,20% from the previous day.

     

    The experts’ forecast for Levi Strauss & Co.’s median target at $23.50, with the highest price at $28.00 and the lowest at $18.00. That would be a 41.82% rise from the current price of $16.57. Their estimation shows a buy signal for Levi Strauss & Co. stock.

    The forward P/E ratio is 15.49 and P/E growth is 3.79, the dividend yield is 3.62%.

    Levi Strauss & Co. posted its quarterly earnings report on October 8th. The company reported $0.31EPS for the quarter, beating analysts’ estimates of $0.27. Levi Strauss & Co. earned $1.45 million during the quarter.  The company had a return on equity of 37.44% and a net margin of 6.85%. The revenue was up 4.3% related to the same quarter in the previous year. Levi Strauss & Co. issued its revenue guidance of $5.882-5.909 billion.

    Selling of Levi Strauss & Co. stock

    The company’s main shareholder Walter J. Haas sold 73,845 shares on Wednesday, November 20th at an average price of $16.53, for $1,220,657.85.
    Previously, on November 13th, Walter J. Haas sold 37,290 shares of the company at an average price of $16.96, for  $632,438.40.
    Two days earlier, on November 11th, Walter J. Haas sold 22,321 shares of stock at an average price of $17.06, for $380,796.26.
    On November 8th, Walter J. Haas sold 50,749 shares at an average price of $17.10, for $867,807.90.

    Hedge funds have new holding positions in the Levi’s

    Commerzbank Aktiengesellschaft FI got a new position in Levi Strauss & Co. at approximately $253,000.
    Acadian Asset Management LLC took a new position at around $174,000.
    Parallel Advisors LLC took a new position at approximately $96,000.
    Aperio Group LLC took a new position at around $62,000.
    NumerixS Investment Technologies Inc got a new position at about $58,000.
    Institutional investors hold 9.21% of the Levi Strauss & Co. stock.

    Experts’ ratings on LEVI

    Bank of America boosted its price target on LEVI from $20.00 to $22.00 and marked the stock as a “buy” in October.
    Guggenheim repeated a “buy” rating in September.
    ValuEngine upgraded Levi Strauss & Co. from a “sell” rating to a “hold” in October.
    Levi Strauss & Co. currently has a consensus rating of “Buy” and a  price target of $24.43.

     

    About Levi Strauss

    The company is founded by Levi Strauss, an immigrant from Bavaria who came to San Francisco in 1850 during the Gold Rush. He brought dry goods for selling to the miners. he recognized the miners’ need for durable pants and hired a tailor to sew clothes out of tent canvas. Denim came later.
    A partnership of three Strauss brothers was built in 1853.
    After Strauss died the leadership of the company passed to the Haas family. By the 1960s, Levi’s jeans became popular globally. In 1971, when the company went public it was operating in 50 countries.

    Levi Strauss & Co designs, and markets jeans, casual dress, pants, skirts, jackets, footwear, and accessories for women, men, and children under the brands: Levi’s, Dockers, Signature by Levi Strauss & Co, and Denizen. The company also authorizes Levi’s and Dockers’ trademarks for many product categories, like footwear, belts, wallets and bags, outerwear, sweaters, dress shirts, kids wear, sleepwear, and hosiery.

    Levi’s is a famous brand but the stock needs a price accumulation before it keeps the advance. Anyway, this is the stock to be watched. Its trends in Europe are strong, rising at 20% a year for the past two years and 14% in 2019. Levi proceeds to diversify its distribution in Europe and it is now 50% direct-to-consumer sales. But the U.S. sales are down and now it represents 30% of Levi’s overall sales.

  • Builders FirstSource Inc. Is Good Long-Term Investment

    Builders FirstSource Inc. Is Good Long-Term Investment

    Builders FirstSource Inc. Is Good Long-Term Investment
    Builders FirstSource Inc is a good long-term investment with the possibility to produce almost 30% of revenue

    By Guy Avtalyon

    Builders FirstSource Inc BLDR stock is, according to analysts, rated as a buy. In November it was upgraded from a hold rating.

    This third-quarter earnings season, many companies reported better earnings per share and beat the experts’ estimations and expectations. There were a lot of outperformed stocks and investors are interested to add them in their portfolios because they want strong returns. But which one or few to choose? The market noise is enormous and it so hard for individual investors to make such a decision.

    Builders FirstSource Inc.

    Builders FirstSource (BLDR) is currently recommended as a buy. This stock is trading with a P/E ratio of 12.74. Meaning, at current prices, you have to pay $12.74 for every $1 in trailing yearly profits. Over the past 52 weeks, BLDR’s P/E ratio has been as high 25.65 and low 10.15. But value investors use the P/S ratio as a metric also. You can find the P/S ratio when divide the stock price by sales.

    On the last day of October Builders FirstSource issued its Q3 earnings report.

    Builders FirstSource’s quarterly earnings were $0.72 per share, meaning it beat experts’ expectations. The earnings per share were $0,67 for the same quarter last year.

    So, we can easily see earnings of 20%. Surprised? For the previous quarter,  it was supposed that this company would report earnings of $0.48 per share. But it delivered earnings of $0.63, showing an increase of 31.25%. For the last 12 months or 4 quarters, Builders FirstSource has exceeded consensus EPS estimates 4 times.

    The company posted revenues of $1.98 billion for the third quarter. This compares to year-ago revenues of $2.12 billion. The company has beaten consensus revenue estimates two times for the last four quarters.

    “Our strong third-quarter growth in sales volume and margins combined with our focus on working capital management generated another quarter of strong cash flow.  We were also pleased to deploy capital on an accretive acquisition, while at the same time, further improving our ratio of net financial debt to Adjusted EBITDA to 2.5 times,” said CFO Peter Jackson.

    BLDR stock is currently trading at $25,36.

    What’s next for the Builders FirstSource stock?

    The tricky question indeed. The price made a slight decline of 0,02% yesterday. You can use one simple measure: the company’s earnings outlook. You have to examine the current earnings expectations given by the experts but most importantly you have to check how their predictions have changed.

    The stock is bullish and Traders-Paradise opinion is the price can go up from $25.50 to $27 over the next 12 months. So, we can say it is profitable to invest in Builders FirstSource stock since the long-term earning potential is about 7.00% in the same period.

    The company’s ABOUT

    The company is a supplier and manufacturer of building materials, components, and construction services. 

    Builders FirstSource provides an integrated solution to its customers offering manufacturing, supply, and installation of building products such as windows, doors, and millwork lines.

    Its products are the factory-built roof and floor trusses, wall panels and stairs, vinyl windows, millwork and trim, and engineered wood designed, cut, and constructed. It constructs interior and exterior doors. 

    The company is headquartered in Dallas, Texas.

    Should you buy the Builders FirstSource stock?

    Traders-Paradise predicts a future increase in values of Builders FirstSource, Inc (BLDR) stock. If you want to hold stock with good return, Builders FirstSource, Inc might be a good option for you. Builders FirstSource, Inc quote is $25.36 at 2019/11/20. Based on previous performances this stock may be worth up to $32 with revenue of almost 28% after a five years period. If you invest $10.000 today in this company, after 5 years, it is possible to have about $12.800.